A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Inclusion Criteria

• •Pathologically confirmed stage IIIB \& IV non-small cell lung cancer other than squamous cell carcinoma
• •Patients with one or more measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
• •Locally diagnosed sensitive EGFR mutation positive (Exon 19 deletion or L858R)
• •ECOG performance 0\~1
• •Age ≥ 19 years and - No previous treatment
• •Adequate organ function by following:
• •ANC ≥1,500/uL, hemoglobin ≥9.0g/dL, platelet ≥100,000/uL
• •Serum bilirubin \< 1 x UNL, AST (SGOT) and ALT (SGPT) \< 2.5 x UNL, If Liver metastasis, Serum bilirubin \< 3 x UNL, AST (SGOT) and ALT (SGPT) \< 5 x UNL
• •Serum Cr ≤ 1 x UNL
• •Patients who have had undergone radiotherapy are acceptable if patients meet all of the following criteria:
• •* No history of irradiation to pulmonary tumor lesions.
• •* In case of palliative irradiation to bone lesions in lung: at least 12 weeks must have passed at the date of registration since the last irradiation of the sites.
• •* In case of irradiation to non-pulmonary sites: at least two weeks must have passed at the date of inclusion since the last irradiation of the sites
• •At the time of registration, at least the following period has passed since last date of the prior therapy or procedure:
• •* Surgery(including exploratory/ examination thoracotomy): 4 weeks
• •* Pleural cavity drainage: 1 weeks
• •* Pleurodesis without anti-neoplastic agents (inclusive of BRM such as Picibanil): 2 week
• •* Biopsy accompanied by incision (including thoracoscopic biopsy): 2 week
• •* Procedure for trauma (exclusive of patients with unhealed wound): 2 weeks
• •* Transfusion of blood, preparation of hematopoietic factor: 2 week
• •* Puncture and aspiration cytology: 1 week
• •* Other investigational product: 4 weeks
• •Written informed consent form